Antimicrobial resistance (AMR) is widely recognized as one of the major global health threats of the 21st century. Yet the way this challenge is being addressed is rapidly evolving. Increasingly, the issue is framed within the One Health paradigm, which integrates human, animal and environmental health.
For the pharmaceutical industry, this shift has significant implications. AMR is no longer viewed solely as a clinical or microbiological concern but as a systemic issue that directly affects pharmaceutical innovation, manufacturing practices and global access to medicines.
Several key documents published in early 2026 illustrate this transformation. Among the most relevant are the European Union AMR surveillance report jointly published by EFSA and ECDC, the WHO draft Global Action Plan on AMR 2026-2036, and the 2026 Antimicrobial Resistance Benchmark developed by the Access to Medicine Foundation.
Taken together, these reports indicate that tackling antimicrobial resistance requires not only scientific innovation but also a broader transformation of the pharmaceutical ecosystem.
European surveillance data: the One Health evidence base
The European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food, published in February 2026 by the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC), represents one of the most comprehensive AMR surveillance exercises in Europe.
The report analyses resistance patterns in bacteria collected from humans, animals and food sources, reflecting the One Health approach adopted by European institutions.
The findings confirm persistent resistance to widely used antimicrobial classes such as ampicillin, tetracyclines and ciprofloxacin in several zoonotic bacteria. These trends are particularly concerning because many of these antibiotics remain essential in both human and veterinary medicine.
According to EFSA, the prudent use of antimicrobials across sectors remains a critical component of preserving their long-term effectiveness. One of the most important insights of the report is the interconnection between antimicrobial use in veterinary settings and resistance patterns observed in human health.
For pharmaceutical manufacturers, these findings highlight the need for integrated strategies that consider the entire antimicrobial lifecycle—from development and production to clinical and veterinary use.
Source: EFSA & ECDC. European Union Summary Report on Antimicrobial Resistance, 2026.
Antibiotic innovation and the limits of the pipeline
While surveillance data reveal the scale of the challenge, the most pressing issue remains the limited global pipeline of new antibiotics.
The 2026 Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation evaluates the performance of 25 pharmaceutical companies, including large multinational firms, generic manufacturers and smaller biotechnology companies.
The analysis examines several dimensions of industry engagement in combating AMR, including:
- antimicrobial R&D pipelines
- access and affordability strategies
- responsible manufacturing practices
- stewardship commitments.
The results highlight a mixed landscape. Some companies are investing in novel antimicrobial approaches, including pathogen-specific therapies and non-traditional modalities. However, overall investment remains constrained by scientific uncertainty and limited commercial incentives.
The benchmark stresses that combating AMR requires more than discovering new antibiotics. It also requires responsible commercialization models, equitable access strategies and global stewardship frameworks.
Source: Access to Medicine Foundation. Antimicrobial Resistance Benchmark 2026.
Responsible manufacturing and environmental impact
Another emerging dimension of AMR is the environmental footprint of antibiotic production.
In recent years, growing evidence has shown that antibiotic residues released into the environment—particularly through industrial wastewater—can contribute to the development of resistant bacteria.
As a result, the 2026 benchmark evaluates pharmaceutical companies on their implementation of responsible manufacturing standards, including:
- monitoring of antibiotic concentrations in wastewater
- environmental discharge limits
- supplier compliance and auditing.
This environmental perspective is one of the clearest expressions of the One Health approach applied to pharmaceutical manufacturing. It recognizes that the fight against antimicrobial resistance extends beyond clinical settings and into industrial and environmental practices.
A new strategic framework for the pharmaceutical industry
Taken together, recent international reports suggest that antimicrobial resistance is becoming a structural driver of change for the pharmaceutical sector.
For manufacturers, the implications extend across several domains:
- strengthening antimicrobial research and innovation
- integrating environmental sustainability into production processes
- embedding stewardship policies into global commercialization strategies.
Within this evolving landscape, One Health is no longer merely a conceptual framework. It is increasingly shaping industrial expectations, regulatory debates and global health governance.
For pharmaceutical companies, understanding and anticipating these shifts will be essential to navigating the future of antimicrobial innovation.
Sources
EFSA & ECDC. European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food. 2026
https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2026.9887
Access to Medicine Foundation. 2026 Antimicrobial Resistance Benchmark
https://accesstomedicinefoundation.org/resource/2026-antimicrobial-resistance-benchmark
